Study of SYS6043 for advanced or metastatic solid tumors
Treatments studied
Part of Cancer, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have an advanced or metastatic solid tumor that has not responded to standard treatments, or you cannot have standard treatments.
- You have at least one measurable tumor (except for some prostate cancers that have spread only to bone – that needs special discussion).
- You are in generally good health (able to do daily activities) and have adequate heart function (LVEF of 50% or more).
- You have not had a prior treatment that targets B7-H3 or certain other antibody-drug conjugates with topoisomerase inhibitors.
- You do not have serious heart, lung, or ongoing infection problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug, SYS6090, combined with other treatments for advanced non-small cell or small cell lung cancer that has spread and can't be removed by surgery. It aims to see if this combination can help shrink or control the cancer, and how safe it is for patients.
This trial tests a new drug, SYN608, in people with advanced or metastatic solid tumors, including breast and ovarian cancer, who have run out of standard treatment options. The drug targets tumors with BRCA mutations or other DNA repair problems, which may make them more sensitive to this treatment.
This trial tests a new drug, SYS6043, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.